Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Susan Licht

Physician Assistant, Medical Newtown, CT Physician Assistant

NPI 1447227798 CMS profile 10997164

172 Mount Pleasant Rd, Newtown, CT 06470

Open in the dashboard

General payments

$10,244

476 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan Licht of Newtown, CT is reported in the CMS Open Payments database as having received $10,244 across 476 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,513 70
2024 General $2,507 99
2023 General $1,937 93
2022 General $1,974 97
2021 General $2,312 117

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Licht
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Susan Licht were reported at $1,513. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Susan Licht Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,312 $156 $41–$563 $132
2022 $1,974 $185 $55–$649 $149
2023 $1,937 $199 $58–$717 $160
2024 $2,507 $206 $62–$740 $164
2025 $1,513 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,857 104 payments
  2. AstraZeneca Pharmaceuticals LP $1,226 51 payments
  3. GlaxoSmithKline, LLC. $1,179 48 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $685 26 payments
  5. Amgen Inc. $579 25 payments
  6. Esperion Therapeutics, Inc. $506 14 payments
  7. Novo Nordisk Inc $464 24 payments
  8. Exact Sciences Corporation $412 17 payments
  9. Lundbeck LLC $366 15 payments
  10. Janssen Pharmaceuticals, Inc $280 17 payments
  11. Other $2,690 135 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,244 476 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $823 39 payments
  2. UBRELVY $744 36 payments
  3. Kerendia $685 26 payments
  4. VRAYLAR $582 36 payments
  5. BREZTRI $521 23 payments
  6. NEXLETOL $506 14 payments
  7. Repatha $502 21 payments
  8. QULIPTA $462 23 payments
  9. AREXVY $455 13 payments
  10. FARXIGA $440 22 payments
  11. Other $6,813 326 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,175

Median for Physician Assistant: 241

Drug cost

$54,184

Median for Physician Assistant: $4,110

Branded share of claims

9.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 19 $19,895
Mounjaro Tirzepatide Brand 20 $19,718
Adderall Xr Dextroamphetamine/Amphetamine Brand 11 $2,418
Atorvastatin Calcium Generic 163 $1,523
Levothyroxine Sodium Generic 120 $1,341
Synthroid Levothyroxine Sodium Brand 15 $1,003
Wixela Inhub Fluticasone Propion/Salmeterol Brand 16 $893
Amlodipine Besylate Generic 113 $693
Losartan Potassium Generic 94 $650
Ezetimibe Generic 19 $573

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AREXVY
$327 — —
Kerendia
$247 — —
UBRELVY
$240 — —
VRAYLAR
$221 — —
BREZTRI
$159 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

476 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record